(Q22252685)

Dimensions Publication ID

Dimensions

1005070242

Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group

6 February 2023

language of work or name

English

0 references

publication date

October 2009

0 references

published in

Neurological Sciences

0 references

volume

30

0 references

issue

S2

0 references

page(s)

155-158

0 references

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS10072-009-0147-2

European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging--measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadi

21 January 2018

1 reference

12 December 2020

Melanoma complicating treatment with natalizumab for multiple sclerosis

1 reference

12 December 2020

Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial

1 reference

12 December 2020

A study of therapy-related acute leukaemia after mitoxantrone therapy for multiple sclerosis

1 reference

12 December 2020

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

1 reference

12 December 2020

Natalizumab plus interferon beta-1a for relapsing multiple sclerosis

1 reference

12 December 2020

Early mitoxantrone-induced cardiotoxicity in secondary progressive multiple sclerosis

1 reference

12 December 2020

Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group

1 reference

12 December 2020

Basic and escalating immunomodulatory treatments in multiple sclerosis: current therapeutic recommendations

1 reference

12 December 2020

Magnetic resonance studies of intramuscular interferon beta-1a for relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group

1 reference

12 December 2020

Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial

1 reference

12 December 2020

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group

1 reference

12 December 2020

Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes

1 reference

12 December 2020

Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Copolymer 1 Multiple Sclerosis Study Group

1 reference

12 December 2020

Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin.

1 reference

12 December 2020

PRISMS-4: Long-term efficacy of interferon-beta-1a in relapsing MS.

1 reference

12 December 2020

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group

1 reference

12 December 2020

alpha4-Integrin antagonism with natalizumab: effects and adverse effects

1 reference

12 December 2020

Mitoxantrone induced congestive heart failure in patients previously treated with anthracyclines

1 reference

12 December 2020

Anti-adhesion therapies

1 reference

12 December 2020

A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis

1 reference

12 December 2020

250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study

1 reference

12 December 2020

Selective treatment of multiple sclerosis

1 reference

12 December 2020

An examination of the results of the EVIDENCE, INCOMIN, and phase III studies of interferon beta products in the treatment of multiple sclerosis

1 reference

12 December 2020

Magnetic resonance imaging results of the PRISMS trial: a randomized, double-blind, placebo-controlled study of interferon-beta1a in relapsing-remitting multiple sclerosis. Prevention of Relapses and Disability by Interferon-beta1a Subcutaneously in

1 reference

12 December 2020

Immunomodulatory agents for the treatment of relapsing multiple sclerosis: a systematic review

1 reference

12 December 2020

Randomized placebo-controlled trial of mitoxantrone in relapsing-remitting multiple sclerosis: 24-month clinical and MRI outcome

1 reference

12 December 2020

Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. The IFNB Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group

1 reference

12 December 2020

Rapid onset mitoxantrone-induced cardiotoxicity in secondary progressive multiple sclerosis

1 reference

12 December 2020

1 reference

12 December 2020

A controlled trial of natalizumab for relapsing multiple sclerosis

1 reference

12 December 2020

Interferons in relapsing remitting multiple sclerosis: a systematic review

1 reference

12 December 2020

European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis

1 reference

https://api.crossref.org/works/10.1007%2FS10072-009-0147-2

7 January 2021

inferred from DOI database lookup

Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis

1 reference

https://api.crossref.org/works/10.1007%2FS10072-009-0147-2

7 January 2021

inferred from DOI database lookup

The cost of delaying treatment in multiple sclerosis: what is lost is not regained

1 reference

https://api.crossref.org/works/10.1007%2FS10072-009-0147-2

7 January 2021